Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.

Clin Transl Sci · 2024 · PMC10958174 · PMID 38515348

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend was observed between the probability of objective response and increasing tislelizumab exposure in patients with ESCC; however, this was not statistically significant ( p = 0.053).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.